Resources

Help guide your patients and their parents or caregivers with these tools and resources.

Identifying High-risk Patients

RSV Protection Guide
Emphasizes the importance of protecting the highest-risk infants first and offers information and resources to help make sure these infants start and stay with SYNAGIS
Patient Eligibility Grid
Helps identify high-risk patients who are eligible for SYNAGIS
Editable Patient ID Log
Allows you to identify and track eligible patients during the RSV season
2014 AAP Birthday Guide
Interactive guide that simplifies identifying infants who are at the highest risk for severe RSV disease during the 2024-2025 RSV season according to the 2014 AAP guidance
2024 NPA Birthday Guide
Interactive guide that simplifies identifying infants who are at the highest risk for severe RSV disease during the 2024-2025 RSV season according to the 2024 NPA guidelines

Other Resources

Tools to help you in your practice

NICU FIrst Dose
Demonstrates the importance of receiving the first dose of SYNAGIS in the NICU, before a patient is discharged to the outpatient setting

RSV Education for Your Patients

RSV Factsheet

Contains information about what RSV is and premature infants at high risk

SYNAGIS Information for Your Patients

SYNAGIS brochure

Educate Parents/Caregivers about SYNAGIS and why their baby may be at high risk

View form en español

Caregiver Action Steps Postcard

Here's what to do when your doctor has prescribed SYNAGIS for your baby

AAP=American Academy of Pediatrics; NICU=neonatal intensive care unit; NPA=National Perinatal Association; RSV=respiratory syncytial virus.

All imagery is for illustrative purposes only.

ALL INFANTS ARE NOT THE SAME

INDICATION

SYNAGIS, 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

Limitations of Use

The safety and efficacy of SYNAGIS have not been established for treatment of RSV disease.

INDICATION & IMPORTANT SAFETY INFORMATION

INDICATION

SYNAGIS, 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

Limitations of Use

The safety and efficacy of SYNAGIS have not been established for treatment of RSV disease.

Contraindications

Previous significant hypersensitivity reaction to SYNAGIS.

Warnings and Precautions

Hypersensitivity Reactions: Anaphylaxis and anaphylactic shock (including fatal cases) and other severe acute hypersensitivity reactions have been reported. Permanently discontinue SYNAGIS and administer appropriate medication if such reactions occur.

Coagulation Disorders: SYNAGIS should be given with caution to children with thrombocytopenia or any coagulation disorder.

RSV Diagnostic Test Interference: Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays.

Adverse Reactions

Serious Adverse Reactions: The most common serious adverse reactions occurring with SYNAGIS are anaphylaxis and other acute hypersensitivity reactions.

Most Common Adverse Reactions: The most common adverse reactions are fever and rash.

Postmarketing Experience: Severe thrombocytopenia and injection site reactions have been identified during post approval use of SYNAGIS.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

These are not all the possible risks associated with SYNAGIS. Please see full Prescribing Information for SYNAGIS, including Patient Information. To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or the FDA at 1-800-FDA-1088.

For Statutory Pricing Disclosure, visit synagishcp.com/wac-pricing.